Bringing you the Best Analytical Legal News
This column will provide all information related to Law Firms.
The firm advised prominent investors such as Elevation Capital, Peak Investments, Venture Highway, and Y Combinator. The issue opened on December 3 and closed on December 5, 2025.
Continue reading
Khaitan & Co appoints Dr. Vimal Choudhary as Chief Operating Officer, bringing over 23 years of global consulting and strategy experience to drive the Firm’s growth and digital transformation.
Continue reading
Cyril Amarchand Mangaldas advised Sheela Foam Limited on further investment in Furlenco via preferential issue and structuring investor rights in the funding round.
Continue reading
Lakshmikumaran & Sridharan advised Sai Parenteral’s Limited and its Singapore arm on the cross-border acquisition of 74.6% stake in Noumed Pharmaceuticals Pty Ltd, Australia.
Continue reading
Cyril Amarchand Mangaldas advised Serum Institute on the proposed sale of its stake in Biocon Biologics to Biocon and the simultaneous subscription of shares in Biocon Limited through a share swap transaction valued at ₹2,250 crore. The deal marks a significant restructuring in India’s biopharmaceutical sector.
Continue reading
Khaitan & Co advised Viatris on the USD 815 million sale of its stake in Biocon Biologics to Biocon via cash payment and preferential share allotment.
Continue reading
Fox & Mandal successfully defended Shalimar before the Calcutta High Court in a passing-off action, securing protection for its distinctive trade dress and packaging.
Continue reading
Cyril Amarchand Mangaldas advised Swiss Parenterals Limited and its promoter on the sale of the remaining 30% stake to Eris Lifesciences Limited through a preferential allotment deal worth ₹423.30 crore.
Continue reading
Framework to provide structured resolution for delay & disruption claims in India
Continue reading
CAM advised Ashoka Buildcon Limited on Macquarie’s ~₹1,715 crore exit from its group entities, providing end-to-end transactional support on the divestment of stakes in Ashoka Concessions Limited and Jaora—Nayagaon Toll Road Company Private Limited.
Continue reading
Khaitan & Co represented the Book Running Lead Managers before the Bombay High Court in writ petitions challenging the WeWork IPO on grounds of alleged inadequate disclosures, with both petitions ultimately dismissed.
Continue reading
SAM advised Eris Lifesciences on acquiring the remaining 30% stake in Swiss Parenterals, making it a wholly owned subsidiary.
Continue reading
The Panel upheld Coinswitch’s claim on all three UDRP criteria, finding confusing similarity, lack of legitimate rights, and bad faith registration and use.
Continue reading
Dr. Shardul S. Shroff receives the ACES 2025 Lifetime Achievement Award for his exemplary leadership, ethical governance and impact across Asia.
Continue reading
The firm provided comprehensive transactional, structuring, and diligence support, marking AION’s full exit from Planetcast and its subsidiaries.
Continue reading
Comprising a fresh issue and offer for sale by promoter shareholders. The IPO saw an exceptional overall subscription of 93.71 times, with QIB demand at 213.08 times.
Continue reading
CAM advised Goldman Sachs (India) Securities Private Limited as placement agent in the ₹7,191 crore sale of 34.3 million equity shares of Bharti Airtel Limited by Indian Continent Investment Limited, executed through on-screen block trades on BSE and NSE.
Continue reading
The deal involves an initial USD 2 billion equity commitment, with an additional USD 4—5 billion planned through debt, marking one of India’s largest private equity investments in the digital infrastructure sector.
Continue reading
SAM advised on the primary issuance, investor participation, and transaction structuring, reinforcing the Firm’s strength in high-value growth and venture capital deals in the AgriTech sector.
Continue reading
The deal marks Omega Hospitals’ entry into the Bengaluru oncology market and forms part of its nationwide expansion strategy. The transaction involved a full exit by Cytecare’s founding and major shareholders.
Continue reading